Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sage Therapeutic Com (SAGE)

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,315,674
  • Shares Outstanding, K 58,908
  • Annual Sales, $ 1,114 M
  • Annual Income, $ 606,070 K
  • 60-Month Beta 1.75
  • Price/Sales 2.05
  • Price/Cash Flow N/A
  • Price/Book 1.27
Trade SAGE with:

Options Overview Details

View History
  • Implied Volatility 97.41% ( +3.00%)
  • Historical Volatility 50.68%
  • IV Percentile 71%
  • IV Rank 34.87%
  • IV High 195.20% on 06/11/21
  • IV Low 45.06% on 06/23/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 9
  • Volume Avg (30-Day) 384
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 3,530
  • Open Int (30-Day) 9,578

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -2.16
  • Number of Estimates 14
  • High Estimate -1.67
  • Low Estimate -2.41
  • Prior Year -2.47
  • Growth Rate Est. (year over year) +12.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.02 +9.16%
on 01/24/22
45.09 -12.80%
on 01/07/22
-3.75 (-8.71%)
since 12/23/21
3-Month
36.02 +9.16%
on 01/24/22
47.75 -17.65%
on 11/04/21
-2.03 (-4.91%)
since 10/26/21
52-Week
36.02 +9.16%
on 01/24/22
88.51 -55.58%
on 03/01/21
-44.16 (-52.90%)
since 01/26/21

Most Recent Stories

More News
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,...

SAGE : 39.51 (+0.51%)
Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises

Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the...

SAGE : 39.51 (+0.51%)
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of...

SAGE : 39.51 (+0.51%)
BIIB : 226.04 (+1.68%)
Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone....

GSK : 44.58 (+0.47%)
BIIB : 226.04 (+1.68%)
ENDP : 3.24 (+1.89%)
SAGE : 39.51 (+0.51%)
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their...

SAGE : 39.51 (+0.51%)
BIIB : 226.04 (+1.68%)
Sage Therapeutics to Host Sage FutureCast Webcast

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,...

SAGE : 39.51 (+0.51%)
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,...

SAGE : 39.51 (+0.51%)
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,...

SAGE : 39.51 (+0.51%)
Artificial Intelligence Could Be About To Replace Your Doctor

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary   London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate....

SAGE : 39.51 (+0.51%)
SAVA : 40.78 (+1.90%)
CMPS : 16.40 (+4.59%)
STIM : 3.50 (+1.45%)
ACHC : 53.60 (+0.83%)
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Lags Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -20.11% and -28.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...

SAGE : 39.51 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

3rd Resistance Point 42.28
2nd Resistance Point 41.20
1st Resistance Point 40.26
Last Price 39.51
1st Support Level 38.24
2nd Support Level 37.16
3rd Support Level 36.22

See More

52-Week High 88.51
Fibonacci 61.8% 68.46
Fibonacci 50% 62.27
Fibonacci 38.2% 56.07
Last Price 39.51
52-Week Low 36.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar